

University of Groningen

## Targeting lysine acetylation in inflammatory lung diseases

van den Bosch, Thea

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2017

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

van den Bosch, T. (2017). *Targeting lysine acetylation in inflammatory lung diseases*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Targeting lysine acetylation in  
inflammatory lung diseases**

**Thea van den Bosch**

The research described in this thesis was carried out at the Department of Chemical and Pharmaceutical Biology (Groningen Research Institute of Pharmacy, University of Groningen, the Netherlands) according to the requirements of the Graduate School of Science (Faculty of Science and Engineering, University of Groningen, the Netherlands).

The research was financially supported by the European Research Council with an ERC starting grant (309782) to Prof. dr. F.J. Dekker.

Printing of this thesis was financially supported by the University Library and the Graduate School of Science, Faculty of Science and Engineering, University of Groningen, the Netherlands.

Cover design: Thea van den Bosch, Ilse Stronks (PersoonlijkProefschrift.nl)

Cover picture: Purchased and adapted from Adobe stock

Layout: Ilse Stronks (PersoonlijkProefschrift.nl)

Printing: Ipskamp printing

ISBN (printed version): 978-90-367-9816-7

ISBN (electronic version): 978-90-367-9815-0

Copyright © 2017 by Thea van den Bosch. All rights reserved. No parts of this thesis may be reproduced or transmitted in any form or by any means without the prior permission in writing of the author.



**rijksuniversiteit  
 groningen**

## **Targeting lysine acetylation in inflammatory lung diseases**

### **Proefschrift**

ter verkrijging van de graad van doctor aan de  
 Rijksuniversiteit Groningen  
 op gezag van de  
 rector magnificus prof. dr. E. Sterken  
 en volgens het besluit van het College van Promoties.

De openbare verdediging zal plaatsvinden op

vrijdag 16 juni 2017 om 14.30 uur

door

**Taatske Frédérique Henriëtte van den Bosch**

geboren op 20 oktober 1989  
 te Groningen

**Promotores**

Prof. dr. F.J. Dekker

Prof. dr. H.J. Haisma

**Beoordelingscommissie**

Prof. dr. N.C. van de Merbel

Prof. dr. M.G. Rots

Prof. dr. W. Vanden Berghe

**Paranimfen**

Jacqueline van den Bosch

Alex van den Bosch



Voor mijn lieve ouders





# Table of Contents

<b>Chapter 1 Introduction and scope of the thesis</b>	<b>13</b>
The NF- $\kappa$ B pathway	15
Lysine acetylation as a regulator of the NF- $\kappa$ B pathway	15
HATs in the NF- $\kappa$ B pathway	15
HAT inhibitors mainly lead to inhibition of the NF- $\kappa$ B pathway	16
HDAC classes	17
Inhibitors of zinc dependent HDACs have ambiguous effects on the NF- $\kappa$ B pathway	17
Model diseases in this thesis: inflammatory airway diseases asthma and COPD	18
HAT and HDAC expression and activity in asthma and COPD	20
HATi and HDACi in asthma and COPD	21
Scope of the thesis	23
References	25
<b>Chapter 2 The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases</b>	<b>31</b>
Abstract	32
Introduction	33
Results	34
C646 inhibits NF- $\kappa$ B activity	34
C646 inhibits pro-inflammatory gene expression expression in RAW264.7 macrophages and precision-cut lung slices	35
C646 increases histone acetylation on H3 residues 18-26	38
C646 inhibits recombinant HDACs	41
C646 decreases tubulin acetylation status	42
Discussion	42
Experimental Section	45
Acknowledgements	50
Author contributions	50
References	51

<b>Chapter 3</b>	<b>A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices</b>	<b>55</b>
	Abstract	56
	Introduction	57
	Results	58
	The 6-alkylsalicylate MG149 inhibits the MYST family HAT MOF with a $K_i$ value of $39 \pm 7.7 \mu\text{M}$	58
	The 6-alkylsalicylate MG149 inhibits histone acetylation in murine precision-cut lung slices	60
	The 6-alkylsalicylate MG149 reduces pro-inflammatory gene expression in murine precision-cut lung slices	62
	Discussion	65
	Experimental Section	67
	Acknowledgements	70
	Author contributions	70
	References	71
	Supporting Information	73
<b>Chapter 4</b>	<b>A novel histone acetyltransferase inhibitor attenuates histone acetylation and inflammatory gene expression in model systems for inflammatory airway diseases</b>	<b>77</b>
	Abstract	78
	Introduction	79
	Results and Discussion	80
	Effect on histone acetylation in RAW264.7 murine macrophages	80
	Effect on SAHA-induced histone hyperacetylation in murine precision-cut lung slices	82
	Effect on pro-inflammatory gene expression in RAW264.7 murine macrophages and murine precision-cut lung slices	85
	Concluding remarks	89
	Experimental Section	89
	Acknowledgements	93
	Author contributions	93
	References	94
	Supporting Information	96

<b>Chapter 5</b>	<b>HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice</b>	<b>99</b>
	Abstract	100
	Introduction	101
	Results	103
	MS-275 affects both pro- and anti-inflammatory gene expression in murine precision-cut lung slices and is particularly effective in affecting inflammatory responses in macrophages	103
	MS-275 increases LPS and IFN $\gamma$ -induced NF- $\kappa$ B p65 transcriptional activity, acetylation, nuclear translocation, and binding at the <i>IL-10</i> promoter in RAW264.7 macrophages	106
	MS-275 robustly attenuates inflammatory gene expression and inflammatory cell recruitment in cigarette smoke-induced neutrophilic airway inflammation in C57Bl/6 mice	111
	MS-275 restores mRNA levels of <i>IL10</i> <i>in vivo</i> but does not affect the CD68 <sup>+</sup> or CD68 <sup>+</sup> /IL-10 <sup>+</sup> cell number in cigarette smoke-induced C57Bl/6 mice	112
	MS-275 restores overall histone acetylation in lung tissue of cigarette smoke-exposed mice	113
	Discussion	115
	Experimental Section	118
	Acknowledgements	129
	Author contributions	129
	References	130
	Supporting Information	133
<b>Chapter 6</b>	<b>Summary and General Discussion</b>	<b>141</b>
	From histones to transcription factors	145
	From recombinant enzymes to HDAC activity in cells	145
	From IC <sub>50</sub> to binding kinetics	146
	Concluding remarks	147
	References	149
	<b>Appendices</b>	<b>151</b>
	Abbreviations	152
	Nederlandse samenvatting	154
	Dankwoord	158
	List of Publications	162
	About the author	164

